Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 19

Results For "case"

1050 News Found

PharmaForceIQ acquires Aktana, launches first “optichannel-in-a-box” platform for pharma
News | January 12, 2026

PharmaForceIQ acquires Aktana, launches first “optichannel-in-a-box” platform for pharma

The integration unifies brand and field strategy, drives executional alignment, and delivers immediate impact measurement


WHO unveils updated HIV guidelines to boost treatment & save lives
News | January 09, 2026

WHO unveils updated HIV guidelines to boost treatment & save lives

The guidelines also support reusing tenofovir and abacavir in later regimens for improved outcomes, cost savings, and programmatic efficiency


Incyte eyes first-line nod for Tafasitamab in aggressive lymphoma
News | January 07, 2026

Incyte eyes first-line nod for Tafasitamab in aggressive lymphoma

Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma (NHL) in adults, represents 40% of all cases worldwide


Dr. Reddy's launches novel recombinant Hepatitis E vaccine ‘Hevaxin’ in India
News | January 07, 2026

Dr. Reddy's launches novel recombinant Hepatitis E vaccine ‘Hevaxin’ in India

It is currently the only vaccine authorized by the Drug Controller General of India (DCGI) for active immunization against HEV in adults aged 18 to 65


FDA grants priority review to Tzield for youngest Type 1 diabetes patients
Drug Approval | January 07, 2026

FDA grants priority review to Tzield for youngest Type 1 diabetes patients

Currently approved for patients eight and older, Tzield could now be used to delay the onset of stage 3 type 1 diabetes (T1D) in children diagnosed with stage 2 T1D


Medera doses final patient in high-dose HFpEF gene therapy trial
Biopharma | January 07, 2026

Medera doses final patient in high-dose HFpEF gene therapy trial

Heart failure affects an estimated 64.3 million people worldwide


Valneva and Serum Institute end chikungunya vaccine partnership
News | January 06, 2026

Valneva and Serum Institute end chikungunya vaccine partnership

Valneva said regaining full rights to the vaccine will allow the company to “assume direct control over its supply chain and commercialization for endemic high-risk countries


BioInvent’s experimental combo shows promise in hard-to-treat ovarian cancer
Clinical Trials | January 06, 2026

BioInvent’s experimental combo shows promise in hard-to-treat ovarian cancer

Pembrolizumab has shown meaningful benefit only when combined with chemotherapy